BR0214112A - Indazolilpirrolotriazinas modificadas c-5 - Google Patents

Indazolilpirrolotriazinas modificadas c-5

Info

Publication number
BR0214112A
BR0214112A BR0214112-4A BR0214112A BR0214112A BR 0214112 A BR0214112 A BR 0214112A BR 0214112 A BR0214112 A BR 0214112A BR 0214112 A BR0214112 A BR 0214112A
Authority
BR
Brazil
Prior art keywords
formula
compounds
useful
growth factor
modified
Prior art date
Application number
BR0214112-4A
Other languages
English (en)
Inventor
Harold Mastalerz
Guifen Zhang
James G Tarrant
Gregory D Vite
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0214112A publication Critical patent/BR0214112A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/009—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone characterised by the material treated
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/45—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
    • C04B41/4584—Coating or impregnating of particulate or fibrous ceramic material
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/00474—Uses not provided for elsewhere in C04B2111/00
    • C04B2111/00793—Uses not provided for elsewhere in C04B2111/00 as filters or diaphragms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Structural Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"INDAZOLILPIRROLOTRIAZINAS MODIFICADAS C-5". A presente invenção provê compostos da fórmula I e seus sais farmaceuticamente aceitáveis. Os compostos da fórmula I inibem atividade de tirosina cinase de receptores de fator de crescimento como HER1, HER2 e RER4 desse modo tornando-os úteis como agentes antiproliferativos. Os compostos da fórmula I também são úteis para o tratamento de outras doenças associadas a vias de transdução de sinal operando através de receptores de fator de crescimento.
BR0214112-4A 2001-11-14 2002-11-12 Indazolilpirrolotriazinas modificadas c-5 BR0214112A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301401P 2001-11-14 2001-11-14
PCT/US2002/036528 WO2003042172A2 (en) 2001-11-14 2002-11-12 C-5 modified indazolylpyrrolotriazines

Publications (1)

Publication Number Publication Date
BR0214112A true BR0214112A (pt) 2004-09-14

Family

ID=23300880

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214112-4A BR0214112A (pt) 2001-11-14 2002-11-12 Indazolilpirrolotriazinas modificadas c-5

Country Status (24)

Country Link
US (2) US6908916B2 (pt)
EP (1) EP1446401B1 (pt)
JP (1) JP4301440B2 (pt)
KR (1) KR20050044441A (pt)
CN (1) CN1615306A (pt)
AR (1) AR037368A1 (pt)
AT (1) ATE524462T1 (pt)
BR (1) BR0214112A (pt)
CA (1) CA2467068A1 (pt)
ES (1) ES2370709T3 (pt)
HR (1) HRP20040422A2 (pt)
HU (1) HUP0402566A3 (pt)
IL (1) IL161616A0 (pt)
IS (1) IS7243A (pt)
MX (1) MXPA04004492A (pt)
NO (1) NO20041983L (pt)
NZ (1) NZ533034A (pt)
PE (1) PE20030712A1 (pt)
PL (1) PL368909A1 (pt)
RU (1) RU2004117549A (pt)
TW (1) TW200300350A (pt)
UY (1) UY27540A1 (pt)
WO (1) WO2003042172A2 (pt)
ZA (1) ZA200403694B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
KR101025675B1 (ko) * 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
ATE418546T1 (de) 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
AU2004212435A1 (en) 2003-02-05 2004-08-26 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine kinase inhibitors
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
WO2006104971A1 (en) 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2008007103A (es) 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
CA2768821A1 (en) * 2009-07-28 2011-02-03 Ube Industries, Ltd. Pyrrolo[2,3-d]pyrimidine derivative
CN102627647A (zh) * 2012-03-20 2012-08-08 南京药石药物研发有限公司 4-氯-5-甲基-1H-吡咯并[2,1-f][1,2,4]三嗪的合成方法
EP2948454B1 (en) 2013-01-24 2017-05-31 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Triazine compounds and a process for preparation thereof
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ATE243697T1 (de) 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivate als crf antagonisten
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) * 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
NZ533034A (en) 2004-11-26
WO2003042172A3 (en) 2004-01-29
KR20050044441A (ko) 2005-05-12
NO20041983L (no) 2004-06-24
HUP0402566A3 (en) 2009-01-28
CA2467068A1 (en) 2003-05-22
US6908916B2 (en) 2005-06-21
EP1446401A4 (en) 2006-04-12
ATE524462T1 (de) 2011-09-15
ES2370709T3 (es) 2011-12-22
TW200300350A (en) 2003-06-01
WO2003042172A2 (en) 2003-05-22
MXPA04004492A (es) 2004-08-11
EP1446401B1 (en) 2011-09-14
US20030186983A1 (en) 2003-10-02
AR037368A1 (es) 2004-11-03
HRP20040422A2 (en) 2005-04-30
NO20041983D0 (no) 2004-05-13
RU2004117549A (ru) 2006-01-10
ZA200403694B (en) 2006-06-28
IS7243A (is) 2004-04-30
PL368909A1 (en) 2005-04-04
EP1446401A2 (en) 2004-08-18
HUP0402566A2 (hu) 2005-03-29
US20050209235A1 (en) 2005-09-22
IL161616A0 (en) 2004-09-27
JP4301440B2 (ja) 2009-07-22
CN1615306A (zh) 2005-05-11
JP2005509030A (ja) 2005-04-07
PE20030712A1 (es) 2003-08-21
UY27540A1 (es) 2003-07-31

Similar Documents

Publication Publication Date Title
BR0214112A (pt) Indazolilpirrolotriazinas modificadas c-5
BR0316755A (pt) Indazolilpirrolotriazinas modificadas por c-6
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
BR0312801A (pt) inibidores de azaindol cinase
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
CA2373990A1 (en) Pyrrolotriazine inhibitors of kinases
DE602005023732D1 (de) Pyrrolotriazinverbindungen
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
ATE353888T1 (de) Chinazolinderivate
BR0208373A (pt) Inibidores da tirosina cinase
TR200102782T2 (tr) Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar
WO2005065266A3 (en) Di-substituted pyrrolotriazine compounds
WO2005058245A3 (en) Synthetic process
DE60112574D1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
DE602006004976D1 (de) Kompetitive atp-kinasehemmer
TH67633A (th) ตัวยับยั้งชนิดเฮเทอโรไซคลิกของไคเนส
TH77753A (th) อนุพันธุ์สตาวโรสปอรินที่เป็นสารยับยั้ง flt3 รีเซพเตอร์ ไทโรซีน ไคเนส แอคติวิตี้
TH77753B (th) "อนุพันธุ์สตาวโรสปอรินที่เป็นสารยับยั้ง flt3 รีเซพเตอร์ ไทโรซีน ไคเนส แอคติวิตี้"

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]